Cases & Deals

  • Home
  • Practices
  • Celgene and Juno Therapeutics announce collaboration for development and commercialization of immunotherapies

Share

Celgene and Juno Therapeutics announce collaboration for development and commercialization of immunotherapies

June 2015

Client(s) Celgene Corporation

Jones Day is acting as tax counsel to Celgene Corporation in its global collaboration with Juno Therapeutics for the development and commercialization of immunotherapies. Under the terms of the collaboration, Celgene has the option to commercialize Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T product candidates. Upon closing, Juno receives an upfront payment of approximately $150 million, and in addition Celgene purchases 9,137,672 shares of Juno's common stock at $93.00 per share.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.